{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:03Z","timestamp":1792784583812,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Atwater grand"},{"name":"Paul Leibson Memorial Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.vaccine.2010.12.020","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T04:46:41Z","timestamp":1292993201000},"page":"1710-1720","source":"Crossref","is-referenced-by-count":45,"title":["Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein"],"prefix":"10.1016","volume":"29","author":[{"given":"Ianko D.","family":"Iankov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana H.","family":"Haralambieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2010.12.020_bib0005","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1053\/j.gastro.2009.01.073","article-title":"Helicobacter pylori in health and disease","volume":"136","author":"Cover","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.vaccine.2010.12.020_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2796.2009.02083.x","article-title":"Infectious agents and lymphoma development: molecular and clinical aspects","volume":"265","author":"Ferreri","year":"2009","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/CMR.00054-05","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"19","author":"Kusters","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.020_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1286-4579(03)00112-6","article-title":"Helicobacter in the developing world","volume":"5","author":"Frenck","year":"2003","journal-title":"Microbes Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2010.12.020_bib0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jcp.2008.060392","article-title":"Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates","volume":"61","author":"Romano","year":"2008","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cca.2007.02.026","article-title":"VacA and HP-NAP, Ying and Yang of Helicobacter pylori-associated gastric inflammation","volume":"381","author":"D\u2019Elios","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2010.12.020_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1523-5378.2005.00339.x","article-title":"Pathogenesis of Helicobacter pylori Infection","volume":"10","author":"Figueiredo","year":"2005","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1365-2958.1999.01584.x","article-title":"The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure","volume":"34","author":"Tonello","year":"1999","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-2836(02)00879-3","article-title":"Structure of the neutrophil-activating protein from Helicobacter pylori","volume":"323","author":"Zanotti","year":"2002","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.femsle.2005.06.008","article-title":"Helicobacter pylori induce neutrophil transendothelial migration: role of the bacterial HP-NAP","volume":"249","author":"Brisslert","year":"2005","journal-title":"FEMS Microbiol Lett"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0055","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4049\/jimmunol.178.3.1312","article-title":"The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo","volume":"178","author":"Polenghi","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1521-4141(200203)32:3<671::AID-IMMU671>3.3.CO;2-X","article-title":"The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells","volume":"32","author":"Montemurro","year":"2002","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.020_bib0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1286-4579(03)00124-2","article-title":"Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori","volume":"5","author":"Montecucco","year":"2003","journal-title":"Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2010.12.020_bib0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/eji.200323726","article-title":"The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils","volume":"33","author":"Nishioka","year":"2003","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.12.020_bib0075","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.191.9.1467","article-title":"The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor","volume":"191","author":"Satin","year":"2000","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbrc.2008.09.072","article-title":"Helicobacter pylori neutrophil-activating protein promotes myeloperoxidase release from human neutrophils","volume":"377","author":"Wang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2010.12.020_bib0085","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1172\/JCI27177","article-title":"The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses","volume":"116","author":"Amedei","year":"2006","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.vaccine.2010.12.020_bib0090","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1462-5822.2008.01217.x","article-title":"The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma","volume":"10","author":"Codolo","year":"2008","journal-title":"Cell Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2010.12.020_bib0095","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jaci.2008.08.016","article-title":"Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein","volume":"122","author":"Del Prete","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1574-695X.2007.00258.x","article-title":"The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent","volume":"50","author":"D\u2019Elios","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-695X.2009.00537.x","article-title":"Helicobacter pylori, asthma and allergy","volume":"56","author":"D\u2019Elios","year":"2009","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1523-5378.2007.00478.x","article-title":"The current status of Helicobacter pylori vaccines: a review","volume":"12","author":"Kabir","year":"2007","journal-title":"Helicobacter"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.020_bib0115","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/erv.09.62","article-title":"Development of vaccines against Helicobacter pylori","volume":"8","author":"Del Giudice","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2007.05.008","article-title":"Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies","volume":"133","author":"Wilson","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.vaccine.2010.12.020_bib0125","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1128\/IAI.72.6.3252-3259.2004","article-title":"Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy","volume":"72","author":"Rossi","year":"2004","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2008.05.054","article-title":"Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study","volume":"135","author":"Malfertheiner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2010.12.020_bib0135","series-title":"Field's virology","first-page":"1401","article-title":"Measles virus","author":"Griffin","year":"2001"},{"issue":"16","key":"10.1016\/j.vaccine.2010.12.020_bib0140","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","article-title":"Attenuated measles virus as a vaccine vector","volume":"25","author":"Zuniga","year":"2007","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2010.12.020_bib0145","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1128\/JVI.00923-07","article-title":"A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge","volume":"81","author":"del Valle","year":"2007","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/426824","article-title":"Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis","volume":"191","author":"Despr\u00e8s","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.virol.2009.02.047","article-title":"Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic","volume":"388","author":"Guerbois","year":"2009","journal-title":"Virology"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2010.12.020_bib0160","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1016\/j.vaccine.2009.01.057","article-title":"Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses","volume":"27","author":"Liniger","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.020_bib0165","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/mt.2009.92","article-title":"Converting tumor-specific markers into reporters of oncolytic virus infection","volume":"17","author":"Iankov","year":"2009","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.vaccine.2010.12.020_bib0270","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.vaccine.2010.12.020_bib0175","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1128\/JVI.73.11.9568-9575.1999","article-title":"Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus","volume":"73","author":"Duprex","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.12.020_bib0180","article-title":"Monoclonal antibody and immunosensor technology","volume":"vol. 23","author":"Campbell","year":"1991"},{"issue":"5517","key":"10.1016\/j.vaccine.2010.12.020_bib0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2010.12.020_bib0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/CVI.00008-08","article-title":"Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity","volume":"15","author":"Haralambieva","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0195","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/JVI.72.2.891-899.1998","article-title":"Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited","volume":"72","author":"Kolakofsky","year":"1998","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.12.020_bib0200","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","article-title":"Measles virus spread and pathogenesis in genetically modified mice","volume":"72","author":"Mrkic","year":"1998","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2010.12.020_bib0205","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1128\/JVI.00593-06","article-title":"Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response","volume":"80","author":"Iankov","year":"2006","journal-title":"J. Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0210","first-page":"93","article-title":"Measles control in developing and developed countries: the case for a two-dose policy","volume":"71","author":"Tulchinsky","year":"1993","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2010.12.020_bib0215","series-title":"Field's virology","first-page":"1305","article-title":"Paramyxoviridae: the viruses and their replication","author":"Lamb","year":"2001"},{"issue":"2","key":"10.1016\/j.vaccine.2010.12.020_bib0220","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1742-4658.2007.06201.x","article-title":"Helicobacter pylori neutrophil-activating protein activates neutrophils by its C-terminal region even without dodecamer formation, which is a prerequisite for DNA protection\u2014novel approaches against Helicobacter pylori inflammation","volume":"275","author":"Kottakis","year":"2008","journal-title":"FEBS J"},{"issue":"39","key":"10.1016\/j.vaccine.2010.12.020_bib0225","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.0403597101","article-title":"Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system","volume":"101","author":"von Messling","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.vaccine.2010.12.020_bib0230","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1128\/JVI.00906-09","article-title":"Protective anti-hepatitis B responses in Rhesus monkeys primed with a vectored measles virus and boosted with a single hepatitis B surface antigen dose","volume":"83","author":"Reyes-Del Valle","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.micpath.2007.06.006","article-title":"Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice","volume":"44","author":"Taylor","year":"2008","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0240","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/j.gastro.2007.01.049","article-title":"Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori","volume":"132","author":"Necchi","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.vaccine.2010.12.020_bib0245","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1086\/605845","article-title":"Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States","volume":"200","author":"Rupnow","year":"2009","journal-title":"J Infect Dis"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2010.12.020_bib0250","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0264-410X(01)00401-7","article-title":"Quantifying the population impact of a prophylactic Helicobacter pylori vaccine","volume":"20","author":"Rupnow","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.12.020_bib0255","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.vaccine.2007.11.010","article-title":"Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis","volume":"26","author":"Low","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2010.12.020_bib0260","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1128\/IAI.01470-06","article-title":"Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations","volume":"75","author":"Taylor","year":"2007","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2010.12.020_bib0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2567.2003.01711.x","article-title":"Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations","volume":"110","author":"Vajdy","year":"2003","journal-title":"Immunology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10017585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T18:40:31Z","timestamp":1592160031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10017585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0264410X10017585"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.12.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}